Physician profile
Parag V Pitroda
NPI 1609897842
$410.77
in general payments reported to CMS, 2019-2025
14 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.76 · 2020: $12.46 · 2021: $63.67 · 2022: $59.28 · 2023: $58.40 · 2024: $15.16 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.47 | 2025 | |
| Amarin Pharma, INC. | $52.47 | 2019-2021 | |
| Pfizer INC. | $47.09 | 2019-2025 | |
| Sanofi Pasteur INC. | $43.57 | 2023 | |
| Glaxosmithkline, LLC. | $37.58 | 2021-2025 | Trelegy Ellipta |
| Dynavax Technologies Corporation | $30.47 | 2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $27.85 | 2021 | |
| Amgen INC. | $27.17 | 2022-2024 | Repatha, Otezla |
| Lilly USA, LLC | $19.20 | 2025 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.26 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2020 | |
| Astellas Pharma US INC | $12.17 | 2019 | |
| Abbvie INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Pitroda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.